Items tagged with Research and development
Janssen Global Public Health to oversee R&D and access strategy development for growing portfolio of transformational medicines
Published online on 3 December, a Lancet Report developed a forward-looking investment agenda to attain dramatic health gains by 2035. The Report emphasises public revenue generation and public financing to be allocated to and within public health budgets especially for the poor populations in the low- and middle-income countries. And it asks for measures including, among others: full exemption of out-of-pocket expenses for the poor; poor-friendly pathways towards universal health coverage; heavy taxation on tobacco and other harmful substances; and reduction or elimination of energy subsidies on air-polluting fuels.
Members of the World Health Organization Executive Board this week moved forward on the long path to new ways to spur research and development for diseases that mainly afflict poor populations. A process has been set for considering – and potentially choosing among – eight projects in the coming months. But bigger questions of alternative systems were left for further discussion.
Following news reports that British pharmaceutical producer AstraZeneca will end its spending on early stage research and development for tuberculosis, malaria and neglected tropical diseases, Médecins Sans Frontières issued a statement saying the move is further proof that substantive change to the global pharmaceutical R&D system is needed.
On January 31, 2014, a report was released that AstraZeneca Group plc ADR (AZN) (hereafter, "AZ") announced that it was closing its Avishkar Research & Development facility in Bangalore, India. The closing, which will affect 168 employees, is part of an effort by the British pharmaceutical firm to refocus its resources in R&D. The closing is to take place later this year.1
José Antonio Bastos, head of doctors without borders (MSF) in Spain, has spoken out against big pharmaceutical companies that "only think in terms of profit" and pay little attention to "real health needs" of the population in developing countries, EurActiv Spain reports.
Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.
TB free breathing in the mines of South Africa: New TB vaccines could transform mining across the region (post)
In this guest post, Kari Stoever, vice president of External Affairs at Aeras, writes about how mine workers are disproportionately affected by tuberculosis (TB) and why there’s an urgent need for new tools against this deadly disease.
Over the last couple of years, news of pharmaceutical patents and India’s attempts to protect and manage its market has caught the attention of intellectual property observers everywhere and the pharmaceutical industry in particular.
This industry needs to forget about intellectual property and pool resources if it is to have any real hope of discovering innovative new medicines, a leading scientist claims.
Page 1 of 24 · Total posts: 01 2 Last→